ID Biomedical Announces Results From Phase II Trial of StreptAvax

ID Biomedical has completed the final analysis of immune responses of adults in its Phase II trial of StreptAvax vaccine, the company's subunit protein-based vaccine against group A streptococcal diseases.

The trial enrolled 90 healthy adult subjects, 70 of whom received StreptAvax and 20 of whom received hepatitis A vaccine as a comparator. All subjects received three doses of vaccine, and serum antibody responses were measured after the third dose.

StreptAvax is designed to induce protective immune responses to 26 different M protein serotypes of group A streptococci, which are responsible for causing the vast majority of disease, including the types that are the most common causes of "strep throat" and invasive infections (so-called flesh-eating disease) in North America as well as the types historically associated with the most feared complication of strep throat -- acute rheumatic fever.

StreptAvax recipients responded to a median of 25 of the different streptococcal peptides in the vaccine, and each peptide elicited a significant immune response in a median of 87 percent of vaccinees. By way of contrast, the group of 20 subjects who received hepatitis A vaccine had no significant antibody increase against any of the streptococcal peptides. The pattern of overall safety established in the Phase I trial continued in this study.